Biodefense Market

The global biodefense market size was valued at USD 13.2 billion in 2020 and is anticipated to expand at a CAGR of 5.8% during the forecast period, 2021-2028. The growth of the market is attributed to the technological advancement that is undertaken in the study of biotechnology and genetic engineering since the past decade which can thereby be re-engineered for defense purposes.
 

Get Free Sample Report

Biodefense is the set of medical plus military measures which are often in response of restoring the biosecurity of a nation against various infectious agents including biological toxins. This measure of national security is placed in order to avoid the threat from any biohazards which can be both artificially made and have the intent to infect animals and the environment or to kill human beings and igniting biological warfare. Common agents that are used for bioterrorism include living organisms such as viruses, toxins, fungi and bacteria. They are used deliberately to cause the widespread infection to the human population of that region to create chaos and to both their social and economic stability. The introduction of the latest technological advancements both in the fields of biotechnology and genetic engineering have helped in the defense departments of the country to counter such threats. The organisms that are responsible for bioterrorism, be it the Zika Virus, Flu or the Ebola Virus, can be easily sampled and obtained, making biodefense an important aspect in the countries across the world.

Biological agents which are responsible for the catalyst action for bioterrorism in past references includes botulism, anthrax and other nuclear and chemical agents which can cause serious economic vandalism in the long run. These experiences have made governments create biodefense treaties, policies and acts that can counter several biological threats, reducing risks, and preparation for response and recovery for bio-incidents. After the anthrax bio-terrorism incident which took place in 2001, The National Institute of Infectious Disease played an important role in the development of strategies & tactics to counter bioterrorism, develop medical products, and the emergence of infectious diseases to carry out constant research to treat, study, diagnose and prevent, be it naturally occurring or deliberate.

Governments of several countries have started the collaboration process with many international partners in the supporting of response activities plus increased awareness. According to the survey conducted by the World Health Organization or the WHO, there are approximately 260,000 people facing the risk of Ebola at the period of November 2019. One year later, the same census now showed that over 550,000 people have got infected with the coronavirus causing the COVID-19 pandemic. Developed economies have been sending medical aids to the countries having extremely weak medical infrastructure and low research capabilities to study the research & development activities along with the diagnosis of Zika, Ebola and the coronavirus. After long studies of research and developmental studies, the COVID-19 biological agent was identified to be a long withstanding air-borne host-seeking infection. With this knowledge, the researchers have concluded the way to learn their weakness and in time make biological variants of the coronavirus for biodefense purposes, making a significant growth in the market during the later periods of the COVID-19 pandemic.

Market Trends, Drivers, Restraints, and Opportunities

• Increase in spending and investing from both the government & private investors, along with the increase in government focus and financing towards biodefense tactics and strategies are the primary reason for the projection of boosting the global biodefense market growth during the forecast period, 2021-2028.
• There has been a rapid growth in the number of cases being affected by biological agents such as the Zika and Ebola. People have become more aware of these causes and with the increasing and occurring cases, there have been several modifications in the biodefense departments to counteract and diagnose them. These modifications in the approval and diagnosis processes are become major factors boosting the global biodefense market growth.
• High prices for the development of biological agents, high cost of services from the company’s perspective and high maintenance cost for assuring the quality of the services required by the defense departments, is anticipated to hinder the global biodefense market growth. This becomes extremely difficult to function in developing countries such as South Africa and Brazil where there is limited military infrastructure with regards to biodefense and there is no streamline between the research facilities and the defense facilities.
• There is the eminent danger of biological agents which can harm the health of the soldiers and other individuals causing negative impact to the entire region. This along with the negative impacts to the environment, causing numerous issues to the environmentalists and nature preservation committees can hamper the biodefense market growth
• R&D investment and technological advancement are expected to offer significant opportunities for the market players. Researchers and scientists of the Merck hospital have now discovered a vaccine for the Ebola called the rVSV-ZEBOV-GP which was authorized by the WHO which can be treatment for both the patients of Ebola and other people. There was also the introduction of Project BioShield Act, a strategic decision to increase the research and development funding for the procurement of medical countermeasures against chemical, radiological, nuclear and biological warfare agents.

Scope of the Report

The report on the global biodefense market size includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Global Biodefense Market Segment Insights

Anthrax segment is projected to represent a large market share
Based on products, the global biodefense market is divided into anthrax, smallpox, botulism, radiation/nuclear, and others. The anthrax segment is expected to constitute the major share of 29.5% of the market in 2019. The major reason attributing to this market growth is the introduction of Bacillus anthracis, which is a bacteria of gram-positive in nature, that causes anthrax to become one of the largest likely utilized weapons in bioterrorism. The spores found in Bacillus anthracis are mostly preferred when they can be released in the environment through water, sprays, powder and food. These substances can last for a long period in any environment and fosters itself through plants, water or soil. According to the NCBI, the bacteria from anthrax is classified to be a tier 1 biological reagent because they can be transmitted from one host to another easily and can cause major health issues and public health impact.

Meanwhile the others segment is anticipated to grow with a significant CAGR during the forecast period, 2021-2028. This segment included viruses such as brucellosis, influenza, food poisoning, Zika, Ebola, tularemia, viral hemorrhagic fever, cholera, plague, and even the coronavirus. The National Institute of Allergy and Infectious Diseases or the NIAID along with the NCBI have started working on vaccine research centres which are primarily working on vaccines, especially the Marburg, Ebola and the coronavirus. The University of Texas located at San Antonio was awarded the contract from the USA Department of Defense or the DoD for the development of vaccinations against tularemia.
 

Get Free Sample Report

 North America is anticipated to dominate the market
On the basis of regions, the global biodefense market is categorized as Asia Pacific, North America, Latin America, Europe and Middle East & Africa. The market in North America is expected to constitute a major share of 87.7% in 2019. This regional market growth can be attributed to the growing research & development expenditure along with the rising in adoption of the latest technology. The demand of biodefense services is increasing rapidly in this region due to the presence of the major market players in the biodefense market, an advantage other regions do not have. The cost of expenditure is significantly lower in North America than that of other economies and thereby more frequency of the use and protection against biological agents is present. However, the market in Asia Pacific is anticipated to expand at a significant CAGR of 10.5% during the forecast period, 2021-2028, as they have prioritized the cost-efficiency perspective of biodefense combined with their growing population. The research and development activities present in these regions are solely focused on prevention of biological threats. Japan and Australia have succeeded in making their biodefense infrastructure on the same level if not more secure than the North American countries, and other nations such as India and China are progressively moving forward.
 

Get Free Sample Report

Segments

Segments Covered in the Report
The global biodefense market size has been segmented in terms of

Products

• Anthrax
• Smallpox
• Botulism
• Radiation/Nuclear
• Others

Regions

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• XOMA corporation
• Altimmune Inc
• Emergent Biosolutions Inc
• Dynavax Technologies Corporation
• SIGA Technologies
• Elusys Therapeutics Inc
• Ichor Medical Systems
• Dynport Vaccine Company
• ClevelandBiolabs
• Bavarian Nordic
• Ology Bioservices
• Alnylam Pharmaceuticals Inc

Competitive Landscape

Major players competing in the global biodefense market are XOMA corporation; Altimmune Inc; Emergent Biosolutions Inc; Dynavax Technologies Corporation; SIGA Technologies; Elusys Therapeutics Inc; Ichor Medical Systems; Dynport Vaccine Company; ClevelandBiolabs; Bavarian Nordic; Ology Bioservices; and Alnylam Pharmaceuticals Inc. These market players are involved in several business strategies such as mergers, acquisitions partnerships, collaborations, capacity expansion, and product launches to enhance their market shares.

For instance, Ichor Medical Systems, in March 2019, entered a collaboration along with the research license agreement deal with AstraZeneca in terms of development, clinical assessments & diagnostics of DNA plasmid constructs. Ichor, which is a private biotech firm from the USA, will have annual and upfront payments to reach their developmental milestones with the help of another private biotech firm from Sweden.